Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBITDA (2016 - 2025)

Historic EBITDA for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$24.5 million.

  • Editas Medicine's EBITDA rose 6261.69% to -$24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.8 million, marking a year-over-year increase of 1298.52%. This contributed to the annual value of -$251.2 million for FY2024, which is 4845.17% down from last year.
  • Per Editas Medicine's latest filing, its EBITDA stood at -$24.5 million for Q3 2025, which was up 6261.69% from -$51.5 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's EBITDA ranged from a high of -$24.0 million in Q4 2023 and a low of -$76.2 million during Q1 2025
  • Its 5-year average for EBITDA is -$52.2 million, with a median of -$51.5 million in 2025.
  • As far as peak fluctuations go, Editas Medicine's EBITDA plummeted by 53667.82% in 2021, and later skyrocketed by 6261.69% in 2025.
  • Over the past 5 years, Editas Medicine's EBITDA (Quarter) stood at -$41.6 million in 2021, then plummeted by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then plummeted by 94.45% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
  • Its EBITDA was -$24.5 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$76.2 million in Q1 2025.